Clinical Trial Update: Memantine Monotherapy for Executive Dysfunction and ADHD [NA]

View source ↗

Summary

The clinical trial evaluating memantine monotherapy for ADHD with executive function deficits has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Attention Deficit Hyperactivity Disorder

Drugs mentioned

• Memantine (memantine)

Snippet

Sponsor: Massachusetts General Hospital | Conditions: ADHD, Executive Function Deficits (EFD's) | NA | Status: WITHDRAWN